Compare Quest Diagnostics Inc (DGX) vs Lockheed Martin Corporation (LMT) Price & Performance

Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.

The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.

Lockheed Martin (LMT) trades at $499.22, down 2.14% on the day, amid a bearish technical signal and recent earnings volatility. The company reported revenue growth to $75.05B in 2025, but net income margin declined to 6.68%. Analyst consensus remains bullish with a $635.33 price target, supported by strong defense spending trends and a 23-year dividend growth streak. Recent news highlights AI integration and F-35 program developments, though fixed-price contract risks persist.

LMT offers value with a P/E of 18.41 and robust cash flow, but faces execution risks from contract missteps and debt levels near 36% of assets. Upside hinges on defense budget continuity and operational efficiency, while margin pressure and competitive threats from peers like Boeing pose challenges. The stock's current discount to analyst targets presents a potential entry point for long-term investors, balanced by near-term technical weakness.